Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Schiff

Showing results (181-190 of 199) with videos related to

Pageof 20
Sort By:
Cancer Treatment Reviews|January 31, 2020
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysisFrancesco Schettini, Tomás Pascual, Benedetta Conte, et al.
Cancer Research|August 11, 2022
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast CancerAgostina Nardone, Xintao Qiu, Sandor Spisak, et al.
Cell Genomics|September 10, 2025
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNAHeather A Parsons, Conor Messer, Katheryn Santos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast CancerJamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Breast Cancer Research and Treatment|November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancerXiaoyong Fu, Rinath Jeselsohn, Resel Pereira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2024
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast CancerCristina Guarducci, Agostina Nardone, Douglas Russo, et al.
Cell Reports|December 3, 2014
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressorKristen L Karlin, Gourish Mondal, Jessica K Hartman, et al.
Science (New York, N.Y.)|December 14, 2011
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesisJessica D Kessler, Kristopher T Kahle, Tingting Sun, et al.
Cancer Research|June 6, 2013
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft modelsXiaomei Zhang, Sofie Claerhout, Aleix Prat, et al.
Pageof 20

Showing results (181-190 of 199) with videos related to

Sort By:
Pageof 20
Cancer Treatment Reviews|January 31, 2020
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysisFrancesco Schettini, Tomás Pascual, Benedetta Conte, et al.
Cancer Research|August 11, 2022
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast CancerAgostina Nardone, Xintao Qiu, Sandor Spisak, et al.
Cell Genomics|September 10, 2025
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNAHeather A Parsons, Conor Messer, Katheryn Santos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast CancerJamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Breast Cancer Research and Treatment|November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancerXiaoyong Fu, Rinath Jeselsohn, Resel Pereira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2024
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast CancerCristina Guarducci, Agostina Nardone, Douglas Russo, et al.
Cell Reports|December 3, 2014
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressorKristen L Karlin, Gourish Mondal, Jessica K Hartman, et al.
Science (New York, N.Y.)|December 14, 2011
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesisJessica D Kessler, Kristopher T Kahle, Tingting Sun, et al.
Cancer Research|June 6, 2013
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft modelsXiaomei Zhang, Sofie Claerhout, Aleix Prat, et al.
Pageof 20